Targeting Colon Cancer Stem Cells with a Curcumin Analogue
Author Information
Author(s): Lin L, Liu Y, Li H, Li P-K, Fuchs J, Shibata H, Iwabuchi Y, Lin J
Primary Institution: Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, The Ohio State University
Hypothesis
Is STAT3 activated in colon cancer stem cells and can its inhibition by GO-Y030 provide a therapeutic benefit?
Conclusion
Inhibition of STAT3 in colon cancer stem cells by GO-Y030 may offer an effective treatment for colorectal cancer.
Supporting Evidence
- ALDH+/CD133+ colon cancer cells expressed higher levels of phosphorylated STAT3 than ALDH-negative/CD133-negative cells.
- GO-Y030 inhibited STAT3 phosphorylation and induced apoptosis in colon cancer stem cells.
- GO-Y030 suppressed tumor growth in mouse models of colon cancer.
Takeaway
Scientists found that a new drug, GO-Y030, can help stop cancer stem cells in the colon from growing by blocking a protein called STAT3.
Methodology
Flow cytometry was used to isolate colon cancer stem cells, and the effects of GO-Y030 on STAT3 phosphorylation and cell viability were examined.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website